The scientific care for prevention: An overview

Kidney International, Supplement

Volumn 67, Issue 94, 2005, Pages

  Perico, Norberto ^b   Codreanu, Igor ^b   Schieppati, Arrigo ^b   Remuzzi, Giuseppe ^a  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; RAMIPRIL; STATINE DERIVATIVE; IRBESARTAN;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DEVELOPING COUNTRY; EARLY DIAGNOSIS; FINANCIAL MANAGEMENT; HEALTH CARE COST; HUMAN; KIDNEY TRANSPLANTATION; MANPOWER; MASS SCREENING; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PUBLIC HEALTH; RENAL PROTECTION; RISK FACTOR; CHINA; CHRONIC DISEASE; COST OF ILLNESS; FUNDING; GLOBAL CHANGE; HEALTH PROGRAM; HEALTH SURVEY; HEART DISEASE; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE; MIDDLE EAST; OBESITY; PHYSICAL ACTIVITY; PREVALENCE; PROTEINURIA; RENAL REPLACEMENT THERAPY; SMOKING; SOUTH AND CENTRAL AMERICA; STROKE; CHRONIC KIDNEY FAILURE; HEALTH; RESOURCE ALLOCATION; REVIEW;

CARDIOVASCULAR DISEASES; HUMANS; KIDNEY FAILURE, CHRONIC; RESOURCE ALLOCATION; WORLD HEALTH;

EID: 15944400595     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (51)

1. WORLD HEALTH ORGANIZATION: The World Health Report 2002, Geneva, World Health Organization, 2002
2. WORLD HEALTH ORGANIZATION: The World Health Report 2003 - Shaping the Future, Geneva, World Health Organization, 2003
3. MURRAY CJL, LOPEZ AD: The Global Burden of Disease, Boston, MA, Harvard School of Public Health, 1996
4. LEEDER S, RAYMOND S, GREENBERG H, LIU H, et al: A Race Against Time: The Challenge of Cardiovascular Disease in Developing Economies, New York, NY: Columbia University, 2004
5. JHA P, CHALOUPKA FJ: Curbing the Epidemic: Governments and the Economics of Tobacco Control, Washington, DC, International Bank for Reconstruction and Development/World Bank, 1999
6. POPKIN BM, DOAK CM: The obesity epidemic is a worldwide phenomenon. Nutr Rev 56:106-114, 1998
7. BUMGARNER R: China: Non-communicable disease issues and options revisited. Soc Prev Med In press:2004
8. FRENK J, BOBADILLA JL, SEPULVEDA J, CERVANTES LM: Health transition in middle-income countries: New challenges for health care. H Policy Plann 4:29-39, 1989
9. BASNAYAR B, RAJAPASHA LC: Cardiovascular and infectious diseases in South Asia: The double whammy. BMJ 328:781, 2004
10. INTERNATIONAL DIABETES FEDERATION: Diabetes Atlas, 2nd ed., Brussels, Internal Diabetes Federation, 2003
11. THOMPSON D, WOLF AM: The medical-care cost burden of obesity. Obes Rev 2:189-197, 2001
12. XUE J, MA J, LOUIS T, COLLINS A: Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 12:2753-2758, 2001
13. LYSAGHT M: Maintenance dialysis population dynamics: Current trends and long-term implications. J Am Soc Nephrol 13:S37-S40, 2002
14. JONES C, MCQUILLAN G, KUSEK J, et al: Serum creatinine levels in the US population: Third National and Nutrition Examination Survey. Am J Kidney Dis 32:992-999, 1998
15. COLLINS AJ: The hemoglobin link to adverse outcomes. Advanced Studies in Medicine 3:S14-S17, 2003
16. KAYSEN GA: The microinflammatory state in uremia: Causes and potential consequences. J Am Soc Nephrol 12:1549-1557, 2001
17. VON ECKARDSTEIN A: Is there a need for novel cardiovascular risk factors? Nephrol Dial Transplant 19:761-765, 2004
18. DE JONG PE, HILLEGE HL, PINTO-SIETSMA SJ, DE ZEEUW D: Screening for microalbuminuria in the general population: A tool to detect subjects at risk for progressive renal failure in an early phase? Nephrol Dial Transplant 18:10-13, 2003
19. RITZ E, MCCLELLAN WM: Overview: Increased cardiovascular risk in patients with minor renal dysfunction. An emerging issue with far-reaching consequences. J Am Soc Nephrol 15:513-516, 2004
20. MOGENSEN CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med 310:356-366, 1984
21. BIGAZZI R, BIANCHI S, BALDARI D, CAMPESE VM: Microalbuminuria predicts cardiovascular events and renal insufficiency in essential hypertensives. J Hypertens 16:1325-1333, 1998
22. HILLEGE HL, FIDLER V, DIERCKS GF, et al: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106:1777-1782, 2002
23. BORCH-JOHANSEN K, PELDT-RASMUSSEN B, STRANDGAARD S, et al: Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 19:1992-1997, 1999
24. HOSTETTER TH, RENNKE HG, BRENNER BM: The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 72:375-380, 1982
25. REMUZZI G, BERTANI T: Pathophysiology of progressive nephropathies. N Engl J Med 339:1448-1456, 1998
26. ZOJA C, BENIGNI A, REMUZZI G: Cellular responses to protein overload: Key event in renal disease progression. Curr Opin Nephrol Hypertens 13:31-37, 2004
27. ISEKI K, IKEMIYA Y, ISEKI C, TAKISHITA T: Proteinuria and the risk of developing end stage renal disease. Kidney Int 63:1468-1474, 2003
28. REMUZZI A, PERICO N, AMUCHASTEGUI CS, et al: Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 4:40-49, 1993
29. ZOJA C, CORNA D, BRUZZI I, et al: Passive Heymann nephritis: Evidence that angiotensin-converting enzyme inhibition reduces proteinuria and retards renal structural injury. Exp Nephrol 4:213-221, 1996
30. PETERSON JC, ADLER S, BURKART JM, et al: Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 123:754-762, 1995
31. LEWIS EJ, HUNSICKER LG, BAIN RP, ROHDE RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
32. THE GISEN GROUP (GRUPPO ITALIANO DI STUDI EPIDEMIOLOGICI IN NEFROLOGIA): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857-1863, 1997
33. JAFAR TH, STARK PC, SCHMID CH, et al: Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. Patient-level meta-analysis. Ann Intern Med 139:244-252, 2003
34. PARVINO H-H, LEHNERT H, BROCHNER-MORTENSEN J, et al: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
35. BRENNER BM, COOPER ME, DE ZEEUW D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
36. LEWIS EJ, HUNSICKER LG, CLARKE WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
37. NAKAO N, YOSHIMURA A, MORITA H, et al: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomized controlled trial. Lancet 361:117-124, 2003
38. ORTH SR, STOCKMANN A, CONRADT C, et al: Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int 54:926-931, 1998
39. PECHTER U, OTS M, MESIKEPP S, et al: Beneficial effects of water-based exercise in patients with chronic kidney disease. Int J Rehabil Res 26:153-156, 2003
40. GAEDE P, VEDEL P, LARSEN N, et al: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003
41. FIORETTO P, STEFFES MW, SUTHERLAND DE, et al: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339:69-75, 1998
42. PERICO N, AMUCHASTEGUI CS, COLOSIO V, et al: Evidence that an angiotensin converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started. J Am Soc Nephrol 5:1139-1146, 1994
43. TRIVEDI HS, PANG MMH, CAMPBELL A, et al: Slowing the progression of chronic renal failure: Economic benefits and patients' perspectives. Am J Kidney Dis 39:721-729, 2002
44. ROSE G: Sick individuals and sick populations. Int J Epidemiol 14:32-38, 1985
45. CORESH J, ASTOR BC, GREENE T, et al: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41:1-12, 2003
46. RAMIREZ SPB, HSU SI-H, MCCLELLAN W: Taking a public health approach to the prevention of end-stage renal disease: The NKF Singapore program. Kidney Int 63(Suppl 83):S61-S65, 2003
47. ISEKI K: The Okinawa Screening Program. J Am Soc Nephrol 7(Suppl 2):S127-S130, 2003
48. MANI MK: Prevention of chronic renal failure at the community level. Kidney Int 63(Suppl 83):S86-S89, 2003
49. PLATA R, SILVA C, YAHUITA J, PEREZ L, et al: The first clinical epidemiological programme on renal disease in Bolivia: A model for prevention and early diagnosis of renal diseases in developing countries. Nephrol Dial Transplant 13:3034-3036, 1998
50. MCDONALD SP, MAGUIRE GP, HOY WE: Renal function and cardiovascular risk markers in a remote Australian Aboriginal community. Nephrol Dial Transplant 18:1555-1561, 2003
51. HENRY D, LEXCHIN J: The pharmaceutical industry as a medicine provider. Lancet 369:1590-1595, 2002